RenovoRx, Inc.
NASDAQ:RNXTBiotechnology
-$0.01 today
- Market cap
- $54.04M
- Beta
- 0.99
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.32
Volume 0.84M
Average 0.29M
RNXT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
RenovoRx, Inc.NASDAQ: RNXT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $1K rose 0.0% year over year, behind the +100.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -30.7% a year.
Context
- Depreciation & amortization amounted to 0.2% of revenue in FY2025, up 0.2 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +0.0% toward the trailing-twelve-month pace of +100.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2K USD
- Year-over-year change
- —
- 4-year CAGR
- -31.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 6K | -33.3% |
| FY2021 | 2021-12-31 | 9K | — |
Depreciation & Amortization vs competitors
How RNXT compares with its peers on the latest reported figures
- RNXT's LTM Mar 2026 depreciation & amortization of $2K is the 3rd largest of the 6 companies compared; the peer median is $0.
- Its year-over-year change of +100.0% is the highest of 3, against a peer median of -46.2%.
- Depreciation & amortization amounts to 0.1% of revenue for RNXT, versus a peer median of 27.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $7.3M | -7.9% | -8.2% | 27.5% | |
| LTM Mar 2026 | $16.56K | -84.4% | +19.7% | — | |
| LTM Mar 2026 | $2K | +100.0% | -30.7% | 0.1% | |
| LTM Dec 2025 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding RNXT) | $0 | -46.2% | +5.7% | 27.5% | |
Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (6.32M) | (9.89M) | (10.23M) | (8.81M) | (11.17M) |
| Depreciation & Amortization | 9K | 6K | 0 | 0 | 2K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 147K | 644K | 1.08M | 1.17M | 1.27M |
| Change in Working Capital | (265K) | 428K | 605K | 280K | (247K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | (96K) |
| Inventory | 0 | 0 | 0 | 0 | (189K) |
| Accounts Payables | 363K | 9K | 27K | 25K | 213K |
| Other Working Capital | (628K) | 419K | 578K | 255K | (175K) |
| Other Non-Cash Items | 517K | 0 | (1.71M) | (1.77M) | (827K) |
| Operating Cash Flow | (5.92M) | (8.81M) | (10.26M) | (9.13M) | (10.97M) |
| Capital Expenditures | (15K) | 0 | 0 | (12K) | (2K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (8M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 5.97M | 2.03M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (15K) | (2.03M) | 2.03M | (12K) | (2K) |
| Debt Repayment | 1.98M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 14.56M | 42K | 5M | 15.02M | 12.1M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.79M | 0 | 8K | 102K | (1.3M) |
| Financing Cash Flow | 19.33M | 42K | 5.01M | 15.12M | 10.85M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 13.4M | (10.8M) | (3.22M) | 5.98M | (130K) |
| Free Cash Flow | (5.93M) | (8.81M) | (10.26M) | (9.14M) | (10.98M) |
RenovoRx, Inc.
NASDAQ:RNXT
Intrinsic Alpha fair value
Locked
Current Price
$1.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.